In vitro and in vivo study of 5-methoxypsoralen skin concentration after topical application

Skin Pharmacology and Applied Skin Physiology

Volumn 16, Issue 2, 2003, Pages 130-136

  Colombo, G ^a   Zucchi, A ^a   Allegra, F ^a   Colombo, P ^a   Zani, F ^a   Santi, Patrizia ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b Department of Pharmacy ^*  (Italy)

Author keywords

Permeability; Psoralen; Psoriasis; Skin distribution; Topical gel

Indexed keywords

BERGAPTEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PSORIASIS; SKIN; TECHNIQUE; TISSUE DISTRIBUTION;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GELS; HUMANS; KERATOLYTIC AGENTS; MALE; METHOXSALEN; MIDDLE AGED; PSORIASIS; SKIN; SKIN ABSORPTION;

EID: 0037230454     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069025     Document Type: Article

References (13)

1. McNeely W, Goa KL: 5-Methoxypsoralen - A review of its effects in psoriasis and vitiligo. Drugs 1998;56:667-690.
2. Hönigsmann H: Phototherapy for psoriasis. Clin Exp Dermatol 2001;26:343-350.
3. British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994;130:246-255.
4. Calzavara-Pinton PG, Zane C, Carlino A, De Panfilis G: Bath-5-methoxypsoralen-UVA therapy for psoriasis. J Am Acad Dermatol 1997;36:945-949.
5. Salo OP, Lassus A, Taskinen J: Trioxalen bath plus UVA treatment of psoriasis: Plasma concentration of the drug and clinical results. Acta Derm Venereol 1981;61:551-554.
6. Saïd S, Makki P, Muret P, Humbert P, Millet J: Psoralen percutaneous absorption across the human whole skin and the epidermis in respect to their polarity (in vitro study). J Dermatol Sci 1997;14:136-144.
7. Treffel P, Humbert P, Makki S, Faivre B, Agache P: Use of surface recovery technique to evaluate percutaneous absorption of 5-methoxy psoralen in humans. Arch Dermatol Res 1991;283:487-489.
8. Motta S, Monti M, Sesana S, Mellesi L, Ghidoni R, Caputo R: Abnormality of water barrier function in psoriasis: Role of ceramide fractions. Arch Dermatol 1994;130:452-456.
9. Fartasch M: Epidermal barrier in disorders of the skin. Microsc Res Tech 1997;38:361-372.
10. Zucchi A, Raho E, Marconi B, San-tini M, Allegra F, Colombo P, Bettini R, Santi P: Plasma and skin concentration of 5-methoxypsoralen in psoriatic patients after oral administration. J Invest Dermatol 2001;117:379-382.
11. Marconi B, Mancini F, Colombo P, Allegra F, Giordano F, Gazzaniga A, Orecchia G, Santi P: Distribution of khellin in excised human skin following iontophoresis in passive dermal transport. J Control Release 1999;60:261-268.
12. Artuc M, Stuettgen G, Schalla W, Schaefer H, Gazith J: Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro. Br J Dermatol 1979;101:669-677.
13. Prognon P, Font G, Manes J, Postaire M, Zini R, Marty JP, Mahuzier G: Etude in vitro de la fixation des psoralènes à la kératine. Thérapie 1985;40:459-463.